MITIGO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MITIGO (MITIGO).
Selective serotonin 5-HT3 receptor antagonist acting on the chemoreceptor trigger zone (CTZ) and gastrointestinal tract.
| Metabolism | Hepatic via CYP2D6, CYP3A4, CYP1A2, and CYP2C9; also metabolized by reduction. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 12-16 hours in patients with normal renal function; approximately 24 hours in elderly or those with mild renal impairment. |
| Protein binding | Approximately 95% bound, primarily to albumin. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid. |
| Bioavailability | Oral bioavailability is 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-10 minutes. |
| Duration of Action | 6-12 hours depending on dose and renal function. |
50 mg orally once daily at bedtime
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30-89 mL/min: no adjustment; eGFR 15-29 mL/min: 25 mg once daily; eGFR <15 mL/min or dialysis: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established |
| Geriatric use | Initiate at 25 mg once daily; increase to 50 mg if tolerated and needed; monitor for hypotension and falls |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MITIGO (MITIGO).
| Breastfeeding | Clonidine is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 1.5. Peak milk levels occur 2-4 hours after maternal dose. No adverse effects reported in infants, but use with caution, especially in preterm or hypotensive infants. |
| Teratogenic Risk | Mitigo (clonidine) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown increased fetal resorptions and delayed ossification; no adequate human studies. Second and third trimesters: Use associated with decreased placental perfusion, fetal bradycardia, and neonatal withdrawal; avoid prolonged use near term. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to dolasetron or any component of the formulation; use in patients with congenital long QT syndrome.
| Precautions | Serotonin syndrome when used with other serotonergic drugs; QT interval prolongation; hypersensitivity reactions; use in patients with hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of hypotension. Fetal monitoring includes heart rate and growth assessments; consider non-stress tests and biophysical profiles in third trimester if used chronically. |
| Fertility Effects | Clonidine may cause transient menstrual irregularities, galactorrhea, and decreased libido. No specific known effects on male fertility; animal studies show no impact on reproductive function. |